How Much Does Jatenzo Cost in Arizona in 2026?

Arizona Retail Pricing for Jatenzo

The average cash-pay price for brand-name Jatenzo at Arizona retail pharmacies sits at approximately $900 per month in 2026. This figure reflects the manufacturer's list price set by Tolmar Pharmaceuticals and matches the national wholesale acquisition cost.

Arizona-specific pricing does not differ substantially from national averages because Jatenzo distribution follows standard specialty pharmacy channels. The drug is dispensed as oral soft-gelatin capsules in 158 mg or 237 mg strengths, taken twice daily with food. A 30-day supply at the 237 mg twice-daily maintenance dose translates to 60 capsules per fill. Pharmacy markup and dispensing fees add minimal variation between retailers, typically staying within $20 to $40 of the base cost. Costco, Walmart, and independent Arizona pharmacies may show small differences, but none substantially undercut the $900 baseline without a discount program or insurance benefit applied 1.

The Swerdloff et al. registration trial (N=166) established that oral testosterone undecanoate dosed at 237 mg twice daily with food achieved eugonadal testosterone levels (300 to 1 to 100 ng/dL) in 87% of participants at day 90 2. This efficacy data supports the standard dosing reflected in Arizona pharmacy pricing.

Insurance Coverage in Arizona

Most Arizona commercial insurance plans place Jatenzo on specialty or non-preferred brand tiers, requiring prior authorization before dispensing. The prior authorization criteria typically demand documented serum testosterone below 300 ng/dL on two morning draws, plus a confirmed etiology from the FDA-approved indication list (Klinefelter syndrome, pituitary disorders, chemotherapy sequelae, or other recognized causes of hypogonadism).

Plans from major Arizona insurers, including Blue Cross Blue Shield of Arizona, UnitedHealthcare, Aetna, and Cigna, each maintain their own formulary placement for Jatenzo. Coverage determination depends on the specific plan tier purchased by the employer or individual. Some plans approve Jatenzo only after failure of injectable testosterone (cypionate or enanthate), treating the oral formulation as a second-line option. Others permit first-line oral TU if the patient has documented needle phobia or injection-site complications.

Co-pays for commercially insured Arizona patients with approved prior authorization range from $50 to $150 per month on preferred specialty tiers, and $200 to $400 per month on non-preferred tiers. High-deductible health plans expose patients to the full $900 until their deductible is met 3.

According to the Endocrine Society's 2018 clinical practice guideline on testosterone therapy, "Testosterone therapy is indicated for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" 4.

Arizona Medicaid and AHCCCS

Arizona's Medicaid program, administered through the Arizona Health Care Cost Containment System (AHCCCS), does not cover Jatenzo. This exclusion applies across all AHCCCS managed care plans, including Mercy Care, Banner University Family Care, Arizona Complete Health, and UnitedHealthcare Community Plan.

The AHCCCS formulary covers injectable testosterone cypionate (approximately $30 to $80 per month) and topical testosterone gel as first-line treatments for male hypogonadism. Oral testosterone undecanoate has not been added to the AHCCCS preferred drug list as of the May 2026 formulary update.

Patients on AHCCCS who require oral dosing due to documented medical necessity (injection intolerance, severe skin reactions to topical formulations) face limited options. The non-formulary exception request process exists but approval rates for Jatenzo under AHCCCS remain very low. Prescribers report that AHCCCS reviewers typically redirect toward compounded alternatives or topical formulations before granting brand-name oral TU coverage.

For the estimated 180,000 Arizona men aged 30 to 65 with biochemical hypogonadism, the Medicaid gap means those without commercial insurance or VA benefits must pursue cash-pay, manufacturer assistance, or compounded pharmacy routes.

Compounded Oral Testosterone Undecanoate in Arizona

Compounded oral testosterone undecanoate is available through licensed 503A compounding pharmacies operating in Arizona. Under federal law (Drug Quality and Security Act, 2013), 503A pharmacies may compound patient-specific prescriptions using bulk drug substances, including testosterone undecanoate, when a valid prescription exists and a prescriber-patient relationship is documented 5.

Arizona Board of Pharmacy regulations permit 503A compounding of testosterone undecanoate capsules. The legality is established through the state's pharmacy practice act alignment with federal 503A provisions. Arizona does not maintain a separate state-level banned compounding list that excludes testosterone undecanoate.

Pricing for compounded oral testosterone undecanoate in Arizona varies by pharmacy but typically ranges from $80 to $200 per month, a substantial reduction from the $900 brand-name cost. Some Arizona compounding pharmacies offer 90-day supply pricing that further reduces the per-month expense.

Key differences between compounded and brand-name Jatenzo that Arizona patients should understand:

The brand-name Jatenzo capsule uses a proprietary self-emulsifying drug delivery system (SEDDS) that promotes lymphatic absorption rather than portal absorption 6. Compounded capsules may use different excipient systems, potentially affecting absorption kinetics, peak-to-trough variability, and the required co-administration with dietary fat. No head-to-head bioequivalence data exists between compounded oral TU and the SEDDS-based Jatenzo formulation.

Patients switching from Jatenzo to compounded oral TU should have follow-up serum testosterone levels drawn at 4 to 6 weeks post-switch to confirm adequate absorption and appropriate steady-state levels.

Tolmar Savings Card and Discount Programs

Tolmar Pharmaceuticals offers a manufacturer savings card for commercially insured patients that can reduce Jatenzo co-pays. The program terms for 2026 allow eligible patients to pay as little as $0 to $75 per month, depending on plan co-pay structure, with the card covering the difference up to a maximum annual benefit.

Eligibility requirements for the Tolmar savings card:

The patient must have commercial insurance (not government-funded coverage including Medicare, Medicaid, TRICARE, or VA). The patient must have a valid prescription for Jatenzo. The card applies at participating Arizona pharmacies, which includes most major retail chains and specialty pharmacies.

Patients without any insurance can explore Tolmar's patient assistance program (PAP), which provides free drug supply to qualifying low-income patients. Income thresholds typically fall at or below 300% of the federal poverty level. Application requires income documentation and prescriber attestation.

GoodRx, RxSaver, and similar discount aggregators show limited savings for Jatenzo in Arizona, typically offering 5% to 15% off the cash price. These platforms work better for generic medications and rarely produce substantial savings on brand-name specialty drugs.

Dr. Ronald Swerdloff, who led the key registration study, noted regarding patient access: "The oral route of testosterone administration offers important advantages for adherence and patient preference, particularly for men who cannot tolerate injections or transdermal formulations" 7.

Telehealth Access to Jatenzo in Arizona

Arizona permits telehealth prescribing of Jatenzo without requiring an in-person visit prior to prescription. Under Arizona Revised Statutes §36-3602, telehealth services carry the same prescriptive authority as in-person encounters for Schedule III controlled substances when the prescriber holds an active Arizona medical license or practices under an interstate compact agreement.

Testosterone undecanoate is classified as Schedule III under the Controlled Substances Act. Arizona telehealth regulations permit Schedule III prescribing via audiovisual telecommunication with proper documentation of medical necessity. This means Arizona residents can obtain a Jatenzo prescription from a licensed telehealth provider without traveling to a brick-and-mortar clinic.

Telehealth platforms serving Arizona patients for testosterone therapy typically charge $99 to $199 for an initial consultation and $59 to $129 for follow-up visits. Lab work (total testosterone, free testosterone, PSA, hematocrit, lipid panel) requires a local blood draw, either through a partner lab network or an existing primary care relationship.

The combination of telehealth prescribing plus a compounding pharmacy relationship allows Arizona patients in rural counties (Apache, Navajo, Greenlee, La Paz) to access oral testosterone therapy without the travel burden that injectable monitoring requires 8.

Cost Comparison: Jatenzo vs. Other Arizona TRT Options

Understanding where Jatenzo fits in the Arizona TRT pricing hierarchy helps patients make informed decisions with their prescribers.

Injectable testosterone cypionate (generic): $30 to $80 per month at Arizona pharmacies. Requires intramuscular or subcutaneous injection every 1 to 2 weeks. Covered by AHCCCS and most commercial plans without prior authorization.

Topical testosterone gel (generic AndroGel equivalent): $50 to $150 per month. Daily application. Transfer risk to household contacts. Covered by most Arizona commercial plans; covered by AHCCCS.

Testosterone nasal gel (Natesto): $500 to $700 per month. Three-times-daily intranasal dosing. Limited formulary coverage in Arizona.

Brand-name Jatenzo: $900 per month cash-pay. Twice daily oral with food. Requires prior authorization for most commercial plans. Not covered by AHCCCS.

Compounded oral testosterone undecanoate: $80 to $200 per month. Twice daily oral with food. Not covered by insurance (compounded products rarely carry third-party reimbursement).

A 2020 analysis published in the Journal of Clinical Endocrinology & Metabolism demonstrated that oral testosterone undecanoate produced testosterone levels within the eugonadal range comparable to injectable formulations, with a different pharmacokinetic profile characterized by higher peak-to-trough fluctuation but elimination of injection-related adverse events 9.

Cardiovascular Monitoring Considerations

The FDA mandated a cardiovascular risk warning for all testosterone products in 2015, updated in 2024 following the TRAVERSE trial (N=5,246). TRAVERSE demonstrated that testosterone replacement in men aged 45 to 80 with hypogonadism and established or high-risk cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a median 33-month follow-up (HR 0.96 to 95% CI 0.78 to 1.17) 10.

For Arizona patients starting Jatenzo, standard monitoring includes: baseline and 3-month hematocrit (hold therapy if hematocrit exceeds 54%), fasting lipid panel, PSA in men over 40, and blood pressure assessment. The oral formulation-specific consideration involves hepatic first-pass effects. The SEDDS technology in Jatenzo routes absorption primarily through the intestinal lymphatic system, bypassing significant hepatic first-pass metabolism 11. Liver function tests at baseline and 3 months are reasonable but not mandated by the FDA label.

Arizona patients on Jatenzo should maintain twice-yearly follow-up (in-person or telehealth) with hematocrit, total testosterone trough levels, and symptom assessment. The trough draw timing for oral TU is immediately before the morning dose, at least 8 hours after the prior evening dose.

Strategies to Reduce Jatenzo Cost in Arizona

For Arizona patients who specifically need or prefer oral testosterone undecanoate, several approaches can lower the effective monthly cost below the $900 list price.

First, apply the Tolmar savings card at the point of sale for any commercially insured prescription. This single step drops most co-pays to $75 or below. Second, request that the prescriber submit prior authorization proactively with documentation of injectable intolerance or topical failure, which strengthens the medical necessity case. Third, ask the prescriber about a dose titration period. Some patients stabilize at 158 mg twice daily rather than 237 mg twice daily, and the lower dose costs proportionally less at some pharmacies that price by capsule count.

Fourth, explore licensed Arizona 503A compounding pharmacies if brand-name cost remains prohibitive after savings programs. Require the compounding pharmacy to provide certificates of analysis and confirm their testosterone undecanoate source meets USP standards. Fifth, for patients meeting income thresholds, the Tolmar patient assistance program eliminates drug cost entirely during the qualification period.

The Endocrine Society guideline recommends that "clinicians should discuss the formulation, route, and cost of testosterone therapy with the patient, considering patient preference, pharmacokinetics, treatment burden, and cost" 12. Arizona patients paying $900 per month for Jatenzo without exploring available cost-reduction pathways may be leaving significant savings on the table.